{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-012679","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.389037+00:00","generated_at":"2026-06-15T18:49:45.058248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GeoVax Q1 2023 net loss $4.04M ($0.15/share); cash $23.85M; clinical progress on CM04S1 and Gedeptin","bullets":["Net loss $4,037,916 ($0.15/share) vs $2,427,515 ($0.34/share) in Q1 2022; R&D expense $2.82M (+112% YoY); G&A $1.45M (+23%).","Cash $23.85M at March 31, 2023, down $3.76M from Dec 31, 2022; no revenue reported.","Phase 2 CM04S1 COVID-19 vaccine trial data presented at World Vaccine Congress shows immunogenicity in immunocompromised patients.","Gedeptin Phase 1/2 cancer trial expanded to three NCI-designated centers; enrollment expected to complete in Q2 2023.","Expanded NIH license rights to include orthopoxviruses (Mpox, smallpox) for MVA-based vaccine development."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-012679","json":"https://secwatch.observer/filing/0001437749-23-012679.json","markdown":"https://secwatch.observer/filing/0001437749-23-012679.md","text":"https://secwatch.observer/filing/0001437749-23-012679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/0001437749-23-012679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/govx20230503_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T18:49:45.058248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d43c9878012b9391b42c67ed1531d8993f8ef93","claim":"GeoVax Labs, Inc. reported three months ended March 31, 2023 results: net income $4,037,916, EPS $0.15 per share.","evidence_excerpt":"Net Loss : Net loss for the three months ended March 31, 2023, was $4,037,916, or $0.15 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/0001437749-23-012679-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"$4,037,916"},{"label":"EPS","value":"$0.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}